SYSTEMATIC REVIEW

REVISED Effects of vitamin D supplementation on 25(OH)D levels and blood pressure in the elderly: a systematic review and meta-analysis [version 2; peer review: 1 approved, 1 approved with reservations]

Farapti Farapti ^{1,2}, Chusnul Fadilla ¹, Niwanda Yogiswara ³, Merryana Adriani¹

¹Department of Nutrition, Faculty of Public Health, Universitas Airlangga, Surabaya, East Java, 60115, Indonesia

²Post Graduate Doctoral Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

³Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia

v2 First published: 22 Jun 2020, 9:633
<https://doi.org/10.12688/f1000research.24623.1>
 Second version: 08 Jul 2020, 9:633
<https://doi.org/10.12688/f1000research.24623.2>
 Latest published: 03 Sep 2020, 9:633
<https://doi.org/10.12688/f1000research.24623.3>

Abstract

Background: Hypertension and vitamin D deficiency are prevalent among the elderly. This study evaluated the effects of vitamin D supplementation on changes in serum 25-hydroxyvitamin D (25(OH)D) levels and blood pressure (BP) in the elderly (age > 60 years).

Methods: Randomized controlled trials from electronic databases on the elderly taking oral vitamin D, until the end of March 2019, were selected. Two reviewers independently screened the literature on the basis of specific inclusion criteria. The primary outcomes were serum 25(OH)D level, systolic BP (SBP), and diastolic BP (DBP) changes.

Results: Our analysis revealed significant differences in serum 25(OH)D level changes between the vitamin D and control groups (mean difference [MD] = 13.84; 95% confidence interval [CI] = 10.21–17.47; $P < 0.000$). There were no significant differences in SBP and DBP changes between the vitamin D and control groups. Subgroup analysis revealed significant differences in SBP changes between the hypertensive and vitamin D-deficient subgroups (MD = -4.01; 95% CI = -7.45 to -0.57; $P = 0.02$ and MD = -1.91; 95% CI = -3.48 to -0.34; $P = 0.02$, respectively), and DBP changes only in the hypertensive subgroup (MD = -2.22; 95% CI = -4.1 to -0.34; $P = 0.02$).

Conclusions: Vitamin D supplementation significantly increases 25(OH)D levels and seems beneficial in lowering BP, specifically in the elderly with elevated BP and vitamin D deficiency.

Keywords

vitamin D, blood pressure, elderly, 25(OH)D) levels

Open Peer Review

Approval Status

	1	2
version 3		
(revision)		
03 Sep 2020	view	view
version 2		
(revision)		
08 Jul 2020	view	view
version 1		
22 Jun 2020		

1. **Alexandre S. Silva** , Federal University of Paraíba, João Pessoa, Brazil

2. **Barbara J. Boucher** , Queen Mary University of London, London, UK

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Farapti Farapti (farapti@fkm.unair.ac.id)

Author roles: **Farapti F:** Conceptualization, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Fadilla C:** Data Curation, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Yogiswara N:** Methodology, Software, Validation, Writing – Review & Editing; **Adriani M:** Supervision, Validation

Competing interests: No competing interests were disclosed.

Grant information: The publication this article was supported by Universitas Airlangga.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Farapti F *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Farapti F, Fadilla C, Yogiswara N and Adriani M. **Effects of vitamin D supplementation on 25(OH)D levels and blood pressure in the elderly: a systematic review and meta-analysis [version 2; peer review: 1 approved, 1 approved with reservations]** F1000Research 2020, 9:633 <https://doi.org/10.12688/f1000research.24623.2>

First published: 22 Jun 2020, 9:633 <https://doi.org/10.12688/f1000research.24623.1>

REVISED Amendments from Version 1

In the newest version of our article, we added a new last author who contributed to the supervision and validation of this manuscript, and a new affiliation for the first author.

Any further responses from the reviewers can be found at the end of the article

Introduction

High blood pressure (BP), or hypertension, is still regarded as one of the most influential factors for cardiovascular diseases, especially in the elderly. An increasingly aging population and the increasing prevalence of hypertension emphasize the importance of proper treatment of hypertension. Nutrient supplementation is an alternative treatment since the elderly have multiple chronic diseases and take multiple drugs^{1,2}. Vitamin D is one kind of steroid hormone and micronutrient synthesized in the skin by exposure to ultraviolet B rays and also obtained through dietary intake or supplementation³. Most vitamin D is distributed in the human body in the form of serum 25(OH)D⁴.

Vitamin D deficiency has become an important public health concern because it could take place at any age, and most countries report deficiency as high in the elderly^{3,5}. Vitamin D has an essential part in metabolism regulation and has a significant role in the pathogenesis of hypertension⁴. However, the result of meta-analyses has revealed that the relationship between serum 25(OH)D levels and a decrease in BP is inconsistent. Qi *et al.* (2017) reported that low serum 25(OH)D levels are not significantly associated with a risk of hypertension⁶. In contrast, other studies demonstrated a significant relationship between low serum 25(OH)D levels and hypertension^{3,7}. Another meta-analysis also proved that the serum level of 25(OH)D was significantly associated with the risk of incident hypertension on the general population³.

The elderly is an age group susceptible to deficiency of this fat-soluble vitamin. Skin aging reduces 7-dehydrocholesterol production to 75%, which is known to play a key role as the main source of vitamin D in the human body⁸. The impaired eating ability in the elderly may also contribute to low levels of vitamin D. Therefore, vitamin D deficiency is often associated with various geriatric syndromes. Low levels of vitamin D affects the activity of endocrine hormones as in sufferers of diabetes mellitus type 2 (T2DM) and cardiovascular functions, such as coronary artery disease, heart failure, stroke, and hypertension⁹. A recent meta-analysis in individuals with vitamin D deficiency showed oral vitamin D3 reduces both systolic BP (SBP) and diastolic BP (DBP) in individuals with hypertension and decreases SBP in individuals above 50 years. In contrast, another study has revealed that in younger women, there is a strong association between high serum 25(OH)D levels and the risk of hypertension³. Since the elderly, defined as individuals of more than 60 years of age, have a high risk of vitamin D deficiency and suffer hypertension^{1,2,10}, it is important to provide a meta-analysis of randomized controlled trials gathering the evidence of the effects of vitamin D supplementation compared to placebo on serum 25(OH)D levels and BP, specifically in the elderly population.

Methods

Data source and study selection

A comprehensive search was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement¹¹. All authors searched independently correlated studies in multiple electronic database including, PubMed, ClinicalTrials.gov, and the Cochrane Library from inception until 29th March 2019 using a combination of keywords and subject headings. One of our search strategies used on PubMed using the following keywords: (vitamin D) AND ((blood pressure) OR (hypertension)) AND (elderly). Further relevant articles were then obtained using manually searching the references of retrieved articles.

Eligibility criteria

All titles and abstracts were screened using Mendeley reference software, and duplications were removed manually. Full text of relevant articles were examined for eligibility criteria. The inclusion criteria were as follows: randomized controlled trial (RCT) design; participants with average age > 60 years; primary outcomes SBP change, DBP change, and serum 25(OH)D level change; and only vitamin D (cholecalciferol) intervention. The exclusion criteria were as follows: nonrandomized study; assessment of the full text of the study not possible; the study control group was not placebo; outcomes relevant to our interest not reported; intervention with combined vitamin D and other nutrients supplementation; and non-English full text.

Data synthesis and analysis

Data from each included article were extracted by three investigators (F.F., C.F., N.Y.) by utilizing a piloted form. If there is any disagreement between the authors, the final decision was made by discussion and majority vote. The following data were extracted: year of publication, year of study, geographic location, sample size, health status of participants, mean age, intervention dose, duration of the study, mean and standard deviation (SD) of serum 25(OH)D levels, SBP, and DBP in both intervention and placebo groups at the baseline and at the end of study, and changes from the baseline.

Each RCT's quality was evaluated using the risk of bias tools developed by Cochrane collaboration evaluating six domains. We assessed the selection bias by evaluating the study description on the method of the randomization, the method of allocation concealment, and evaluated if there is difference in baseline between the two groups. Performance and detection bias were evaluated by finding a description about the blinding method. Attrition bias was assessed by calculating the number of participants that withdrew from the study. Reporting bias and other bias were then evaluated if there found any concern not addressed in the other domain¹².

The continuous data were presented as mean difference (MD) and SD. Where the change in mean (Δ Mean) was not available, we calculate the change by subtracting post intervention outcome with the baseline data. When a study did not report enough information of the change on SD (Δ SD), we calculated the data imputation applying the formula for imputing SD from baseline¹³:

$corr = (SD_{baseline}^2 + SD_{post}^2 - SD_{change}^2) / (2 \times SD_{baseline} \times SD_{post})$

ΔSD was then calculated as:

$$\Delta SD = \sqrt{(SD_{baseline}^2 + SD_{post}^2 - 2 \times corr \times SD_{baseline} \times SD_{post})}$$

To calculate the estimated effect size on MD, we used random-effect model if there was heterogeneity found using X^2 test and I^2 test¹⁴. p value of <0.10 and $I^2 > 50\%$ were considered high. Otherwise, the fixed-effects Mantel–Haenszel model was used. We performed univariate meta-regression analyses to evaluate differences in the continuous outcome variable. Analyses of subgroups were conducted to assess predefined sources of heterogeneity. Dose of supplementation, duration of the study, treatment regimen, hypertension, and vitamin D status were considered as sources of heterogeneity. We assessed publication bias by visual assessment on graphical funnel plots with Egger's regression test of asymmetry¹⁵.

All statistical analyses were performed using STATA 16.0 (STATA Corporation). P value < 0.05 was considered statistically significant.

Results

Study characteristics

Figure 1 presents the flowchart of this study. We screened 980 articles. Of those, 28 were excluded because of duplicate publication, and 42 articles were assessed for eligibility criteria. Of those, 30 were not eligible to be included. Finally, 12 RCTs^{16–27} were included in the quantitative synthesis. The quality assessment demonstrated that almost all of the included studies has a low risk of bias. The results for quality assessment was summarized in *Extended data: Figure S1*²⁸.

Table 1 summarizes the characteristics of the included RCTs. The RCTs were conducted in different continents: Asia²³,

Figure 1. PRISMA flowchart. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Table 1. Supplementation of vitamin D on 25(OH)D serum and blood pressure in the elderly.

Authors	Countries, continent	n	Subject condition	Average age (years)	Before intervention		Dose	Time (wk)	After intervention	
					25(OH)D ng/mL	BP (mmHg)			25(OH)D ng/mL	BP (mmHg)
Chen, et al. ²³ (2014)	China, Asia	126	-HT grade I-II -Consume nifedipine 30 mg/d	62.5±9.1	19.4±11.6	SBP: 132.1±9.4 DBP: 75.1±9.1	2,000 IU/day	24	34.1±12.2*	ΔSBP: -6.2* ΔDBP: -4.2*
Wood, et al. ¹⁶ (2012)	UK, Europe	265	Healthy post-menopausal women	63.5±1.9	13.12±5.2	SBP: 128.2±13.8 DBP: 77.7±7.3	400 IU/day	48	46.1±5.2*	ΔSBP: -2.2 ΔDBP: -2.5
				64.1±2.3	13±5.5	SBP: 129.2±15.6 DBP: 76.9±8.1	1,000 IU/day	48	55.9±5.5*	ΔSBP: -1.5 ΔDBP: -0.9
Witham, et al. ²² (2013)	UK, Europe	159	-ISH -25(OH)D levels <30ng/mL	76.9±4.8	18±6.0	SBP: 163±11 DBP: 78±7	100,000 IU/3 month	48	26±6.0*	SBP: 163±18 DBP: 78±9
						SBP: 149.6±24.0 DBP: 81.7±12.4	100,000 IU once	32	25.2±8	SBP: 141.4±16.6* DBP: 77.1±11.7
Witham, et al. ²¹ (2010)	UK, Europe	61	-T2DM -25(OH)D serum <40 ng/mL	65.3±11.1	16.2±5.6	SBP: 145.1±25.0 DBP: 80.7±14.3	100,000 IU once	64	23.6±7.2	SBP: 144.6±20.4 DBP: 79.6±11.9
				63.3±9.6	19.2±8.4	SBP: 145.1±25.0 DBP: 80.7±14.3	200,000 IU once	32	31.7±12.4*	SBP: 136.8±12.9* DBP: 74.4±9.8
						SBP: 135.4±16.8 DBP: 83.2±10.1	200,000 IU once	64	30.5±12*	SBP: 139.5±15.4 DBP: 77.6±11.7
Sollid, et al. ²⁴ (2014)	Norway, Europe	511	Prediabetes	62.1±8.7	24±8.8	SBP: 122.3±13.1 DBP: 72.5±7.6	20,000 IU/wk	48	42.4±9.7*	ΔSBP: -2.9±13.7 ΔDBP: -4.6±8.9
Gepner, et al. ¹⁷ (2012)	Wisconsin, American	114	-Post-menopausal women -25(OH)D levels >10 and <60 ng/mL	64.1±3	30.3±10.7	SBP: 131.4±8.1 DBP: 78.1±7.5	2,500 IU/day	16	46.0±9.3*	ΔSBP: -0.3±8.4 ΔDBP: -0.7±5.1
			-Arterial HT							
Pliz, et al. ²⁵ (2015)	Austria, Europe	188	-25(OH)D serum <30 ng/mL -Ongoing antihypertensive treatment	60.1±11.3	22.0±5.5	SBP: 145 ± 9.2 DBP: 82 ± 10.5	2,800 IU/day	32	36.2±7.3*	SBP: 130.3±9.3 DBP: 77.8±8.2
Sugden, et al. ²⁶ (2008)	Scotland, Europe	34	-T2DM -25(OH)D serum <20ng/mL -6 weeks stable medication	64.9±10.3	16.1±4.1	SBP: 145 ± 9.2 DBP: 82 ± 10.5	100,000 IU once	32	25.3±6.7*	ΔSBP: -7.3±11.8* ΔDBP: -2.2±8.6

Authors	Countries, continent	n	Subject condition	Average age (years)	Before intervention		Dose	Time (wk)	After intervention	
					25(OH)D ng/mL	BP (mmHg)			25(OH)D ng/mL	BP (mmHg)
Larsen, <i>et al.</i> ²⁰ (2012)	Denmark, Europe	112	-Arterial HT -Unchanged medications during study	61±10	23.0±9.0	SBP: 132 ± 10 DBP: 77 ± 6	3,000 IU/day	80	SBP: 130±11 DBP: 76±7	
					<32				44.0±9.0*	ΔSBP: -4* ΔDBP: -3*
Stricker, <i>et al.</i> ²⁷ (2012)	Switzerland, Europe	76	-Chronic Peripheral Arterial Disease -25(OH)D serum <30 ng/mL	72.9±8.7	16.3±6.7	SBP: 133±18.5 DBP: 73±8.2	100,000 IU once	4	SBP: 136±18.7 DBP: 73±8.1	
									24.3±6.2*	
Sluyter, <i>et al.</i> ¹⁸ (2017)	New Zealand, Oceania	517	-Both men and women aged 50–84 years	63.3±8.6	11.1±3.2	SBP: 137.4±16.8 DBP: 78.9±10.7	initiation 200,000 IU, next 100,000 IU/month	48	SBP: 128.9±16.1 DBP: 73.7±9.9	
									23.2*	
Tomson, <i>et al.</i> ¹⁹ (2017)	UK, Europe	305	-Participants aged minimum 65 years -Not taking >400 IU vitamin D daily	71		SBP: 132.7±21.1 DBP: 78±11.3	4,000 IU/day	48	SBP: 132.5±1.43 DBP: 77.2±0.9	
				72	15.7	SBP: 131.8±17.1 DBP: 76.6±10.3			43.1±0.8*	SBP: 131.8±1.51 DBP: 76.6±0.96

HT, hypertension; 25(OH)D, 25-hydroxyvitamin D; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; ΔSBP/DBP, changes of SBP/DBP; wk, weeks; ISH, isolated systole hypertension; T2DM; type 2 diabetes mellitus; *, significant

Europe^{19–22,25–27}, America¹⁷, and Oceania¹⁸. All were placebo controlled and published in English. The mean age of the participants was 65.5 years with differing health conditions. Only three RCTs included participants without certain medical criteria but with some conditions that indicated vitamin D deficiency, including postmenopausal women^{16,17} and those taking vitamin D supplements < 400 IU¹⁹. In addition, several RCTs targeted conditions related to blood sugar levels, such as T2DM^{21,26} and prediabetes²⁴. Hypertension patients were also the subjects of several RCTs, which focused on isolated systole hypertension (ISH)²², arterial hypertension^{20,25}, and essential hypertension²³.

The type of hypertension affected the baseline BP of the participants. The BP varied; some participants had hypertension, whereas others had normal BP. SBP in all participants ranged from 109.2 to 174 mmHg, whereas DBP ranged from 64.8 to 95 mmHg. High SBP usually occurred in ISH and was most commonly found in the elderly. However, on average, in each RCT, the participant's BP was categorized as prehypertension or hypertension (>120/80 mmHg). Hypertension and diabetes experienced by the elderly made it difficult for the participants to be excluded on the basis of medications. Therefore, some of the RCTs had inclusion criteria that required participants not to change their medical treatment throughout the study duration^{20,26,27}, because the use of different drugs affects vitamin D intervention. In their study at one of the general hospitals in Beijing, China, Chen *et al.* (2014) included participants who were taking 30 mg/dL of nifedipine²³. Another factor that may influence the effectiveness of vitamin D supplementation was baseline 25(OH)D levels before the intervention. Some of the RCTs had set serum 25(OH)D limits to <20²⁶, 30^{22,25,27}, 40²², or 60 ng/mL¹⁷; all these values indicate deficiency in vitamin D.

25(OH)D levels change

Table 1 shows that most participants revealed baseline data of mean 25(OH)D levels <20 ng/mL, and the maximum was

30 ng/mL¹⁷. Eight RCTs evaluated changes of 25(OH)D levels after giving vitamin D intervention. The 1293 participants were divided into treatment (n = 641) and control groups (n = 652). Pooling data revealed that the vitamin D group had a significant higher serum 25(OH)D levels compared to the control group (MD = 13.84; 95% CI = 10.21–17.47; $P < 0.0001$). We observed heterogeneity among the RCTs ($I^2 = 93\%$), so we selected a random-effects model (Figure 2).

BP change

The change of SBP and DBP was synthesized from 12 RCTs. We did not observe heterogeneity among the RCTs ($I^2 < 50\%$), so we selected a fixed-effects Mantel-Haenszel model. Pooled analysis revealed that overall, the SBP change (MD = -0.83; 95% CI = -1.88 to 0.23; $P = 0.12$) and DBP changes (MD = 0.40; 95% CI = -1.00–0.19; $P = 0.18$) in vitamin D group were not significant compared with the control group. The effects of vitamin D on SBP and DBP were summarized as forest plots presented in Figure 3 and Figure 4. The funnel plots of SBP change and DBP change are summarized in Figure 5. Our analysis showed that there was no publication bias when examining funnel plots and the result of Egger's test of asymmetry for SBP change and DBP change ($p = 0.158$; $p = 0.069$; respectively).

Table 2 and Table 3 present the pooled estimated effect size of vitamin D on the change of SBP and DBP, on the basis of BP baseline, vitamin D status baseline, intervention dose, treatment duration, and treatment regimen. Our analysis indicate that vitamin D supplementation had no significant influence on SBP and DBP changes on the basis of dose, duration, and treatment regimen. However, subgroup analysis revealed a marginal trend toward significance in terms of DBP changes with treatment duration ≤ 6 months (MD = -0.82; 95% CI = -1.66 to -0.02; $P = 0.05$). Subgroup analysis by hypertensive and deficiency of vitamin D status indicated that vitamin D supplementation could significantly reduce SBP (MD = -4.01; 95% CI = -7.45 to -0.57; $P = 0.02$ and MD = -1.91; 95% CI = -3.48 to -0.34;

Figure 2. Forest plot of 25-hydroxyvitamin D changes from the baseline. The overall effect size estimate is represented by the red dashed line. SD, standard deviation; CI, confidence interval.

Figure 3. Forest plot of systolic blood pressure changes from the baseline. The overall effect size estimate is represented by the red dashed line. CI, confidence interval; SD, standard deviation.

Figure 4. Forest plot of diastolic blood pressure changes from the baseline. The overall effect size estimate is represented by the red dashed line. CI, confidence interval; SD, standard deviation.

Figure 5. Funnel plot assessing publication bias for the effect of (a) systolic blood pressure (BP) change and (b) diastolic BP change.

Table 2. Subgroup analysis of SBP changes.

	Trials	MD (95%CI)	p-Value	I ² (%)
BP baseline				
Hypertension baseline	3	-4.01 (-7.45,-0.57)	0.02*	78
Normal baseline	9	-0.50 (-1.61,0.61)	0.38	9
Vitamin D baseline				
Vitamin D deficiency	8	-1.91(-3.48,-0.34)	0.02*	55
Normal baseline	4	0.06 (-1.37,1.48)	0.93	0
Duration				
≤ 6 months	8	-1.13 (-2.61,0.35)	0.13	61
> 6months	4	-0.51 (-2.02,0.99)	0.51	16
Intervention dose				
≤ 2000 IU/d	2	-0.21 (-3.09,2.67)	0.88	68
> 2000 IU/d	6	-0.47 (-2.07,1.14)	0.57	16
Regiment treatment				
Daily	6	-0.41 (-1.81,1)	0.57	26
Intermittent	6	-1.38 (-2.98,0.22)	0.09	65

SBP, systolic blood pressure; BP, blood pressure; MD, mean difference; CI, confidence interval.

$P = 0.02$, respectively). However, we found a significant difference in DBP changes only in the hypertensive subgroup (MD = -2.22; 95% CI = -4.1 to -0.34; $P = 0.02$) (Table 2 and Table 3). The forest plot of each subgroup analysis is available as *Extended data*: Figure S2²⁸. Our study provided enough observations to conduct univariate meta-regression, summarized in Table 2 and Table 3. The result for SBP change was presented as bubble plots in Figure 6.

Discussion

Effects of vitamin D on serum 25(OH)D levels

Serum 25(OH)D levels has a major role as a marker for determining vitamin D status in humans. As mentioned before,

most vitamin D circulates in human body in the form of 25(OH)D. This is a result of vitamin D metabolism from the skin and vitamin D intake and binds to vitamin D-binding protein, which has a half-life of 2–3 weeks. The clinical practice guidelines issued by the Institute of Endocrinology has defined vitamin D deficiency as levels of 25(OH)D below 20 ng/mL²⁹. In addition, the average normal value for serum 25(OH)D levels for all ages is 30 ng/mL, whereas in the elderly it is >20 ng/mL or 50 nmol/L³⁰.

Deficiency in vitamin D could be caused by physiological and pathological factors in the elderly. One of the most common physiological factors is decreasing pre-vitamin D production

in the skin. The reasons are that compared with young adults, the skin's capacity to produce vitamin D decreases by 75% at 70 years^{29,31}. In addition, the elderly has a tendency to wear closed clothing for fear of flu, thus causing minimal exposure to ultraviolet B rays⁹. Their food intake decreases because of a decrease in chewing ability and financial conditions³⁰. Also, decreased calcium absorption results in impaired vitamin D metabolism and decreased kidney function²⁹⁻³⁴. Pathological factors are related to organs that play a role in the digestion

and metabolism of vitamin D. Decreased bioavailability in the digestive tract (malabsorption due to disease) inhibits vitamin D metabolism. Patients with liver disease can suffer from vitamin D hydroxylation disorders. Kidney pathologies, such as nephrotic syndrome and chronic kidney disease, increase vitamin D activation disorders³⁴. However, the 12 RCTs included in this study excluded participants with pathological conditions that might cause vitamin D deficiency.

One of the main findings of the present meta-analysis was vitamin D supplementation has significant effect on serum 25(OH)D levels among the elderly. It increases serum 25(OH)D levels in people that are older than 60 years old. Almost all studies included have revealed a significant increase in serum 25(OH)D levels from the baseline. The contradictory result was shown by Witham *et al.* (2010) that inconsistent with a previous study by Sugden *et al.* (2008), which has revealed a significant difference between the treatment and control groups with same doses and duration²⁴. Another study has reported increasing serum 25(OH)D levels at follow-up in the vitamin D group, with no change in the placebo group¹⁸. The relationship between serum 25(OH)D levels and a decrease in BP is still debatable. A meta-analysis of observational cross-sectional and prospective studies on general populations has proven the relationship between serum 25(OH)D levels and the risk of incident hypertension³. However, a newer meta-analysis showed oral vitamin D3 has no significant effect on blood pressure in individuals with vitamin D deficiency⁵. To the best of our knowledge, this is the first study that analyses the effects of vitamin D on serum 25(OH)D levels, the gold standard to measure vitamin D status in humans.

Effects of vitamin D on BP

This study included research from four different continents. However, characteristically there are no specific differences for each continent. The results were random and more relevant to the baseline data and effect of the RCT itself. The present study

Table 3. Subgroup analysis of DBP changes.

	Trials	MD (95%CI)	p-Value	I ² (%)
BP baseline				
Hypertension baseline	3	-2.22 (-4.1,-0.34)	0.02*	0
Normal baseline	9	-0.20 (-0.83,0.42)	0.52	4
Vitamin D baseline				
Vitamin D deficiency	4	-0.55 (-1.38,0.28)	0.20	40
Normal baseline	8	-0.25 (-1.1,0.59)	0.56	0
Duration				
≤ 6 months	8	-0.82 (-1.66,0.02)	0.05	9
> 6 months	4	-0.41 (-0.83,0.86)	0.97	22
Intervention dose				
≤ 2000 IU/d	2	0.69 (-0.76,2.15)	0.35	78
> 2000 IU/d	6	-0.41 (-1.33,0.51)	0.38	0
Regimen treatment				
Daily	6	-0.09 (-0.87,0.68)	0.81	34
Intermittent	6	-0.83 (-1.75,0.08)	0.07	0

DBP, diastolic blood pressure; BP, blood pressure; MD, mean difference; CI, confidence interval.

Figure 6. Bubble plot of univariate random-effects meta-regression. (a) Participant blood pressure baseline and the mean difference (MD) in systolic blood pressure (SBP) change; **(b)** Participant 25(OH)D baseline and the MD in SBP change. Each circle characterizes a study and the size of the circle reflects the influence of that study on the model. The regression prediction is represented by the solid line.

provides evidence that although the supplementation could increase serum 25(OH)D levels, there was no significant difference in SBP and DBP changes compared with the control group. It means that the increasing serum 25(OH)D levels were not followed by decreasing BP among elderly. Several studies have revealed not only a relationship between an increase in serum 25(OH)D levels and a decrease in BP after vitamin D supplementation but also a significant change in other conditions, such as parathyroid hormone, serum calcium, renin, and angiotensin II levels^{16,20,23}, indicating that vitamin D regulates a decrease in BP through various mechanisms. The effect of vitamin D supplementation on a decrease in BP is inconsistent in several studies. Some studies have reported that vitamin D supplementation can reduce BP, although only SBP, so vitamin D supplementation can be a supportive therapy for hypertension^{8,21,26}. Similar to our result, a meta-analysis by Golzarand *et al.* has revealed that vitamin D supplementation is only associated with an increase in serum 25(OH)D levels, not SBP or DBP³⁵. Meanwhile, according to Chen *et al.* (2014), vitamin D supplementation that complements 30 mg/dL nifedipine in patients with grade I or II essential hypertension can reduce SBP or DBP²³. They were the first to look at the effectiveness of the interaction between vitamin D and specific drugs in contrast to other studies that only provide inclusion criteria in the form of no change in medication consumption.

Several meta-analyses have been conducted to evaluate the association between vitamin D and BP. The findings of the meta-analysis of observational studies on general populations have proven the association between vitamin D status and the risk of incident hypertension^{3,7,8}. However, the association between vitamin D and hypertension is not causal, so placebo-controlled RCTs are required in order to prove the effects of vitamin D on BP. Previous RCTs and meta-analyses have revealed that vitamin D might be beneficial in lowering BP, especially in vitamin D-deficient patients with hypertension, which is similar to our results^{4,18}. In contrast to our findings, Ke *et al.* (2015) reported no increased risk of hypertension in the elderly or in vitamin D-deficient participants; however, their research involved a prospective study design³. The newest meta-analysis has revealed that vitamin D has no significant effect on BP in vitamin D-deficient people; it reduces SBP in vitamin D-deficient people older than 50 years and in people with both vitamin D deficiency and hypertension⁵. However, a previous meta-analysis involved subjects between 18 and 74 years old and serum 25-OHD are lower than 20ng/mL, and subgroup analysis used criteria older than 50 years old. Meanwhile, our study involved subjects with the mean age more than 60 years, according to WHO definition for elderly¹⁰.

The other important finding in our study was significant differences in SBP and DBP changes among the hypertensive subgroup. Previous meta-analyses have also revealed a significant effect of vitamin D on BP in patients with hypertension at the baseline and no significant decrease in normotensive patients at the baseline^{5,36}. In contrast to our findings, a meta-analysis by Golzarand *et al.* (2016) showed that vitamin D showed hypotensive effects in both healthy and hypertensive subjects³⁵.

To the best of our knowledge, there has been no research that suggests that there are differences in the metabolism of vitamin D in the elderly with hypertension and norm tension, except secondary hypertension associated with kidney organs³⁷. Decreased BP also occurs in arterial hypertension patients who have vitamin D deficiency. Patients with deficiency in vitamin D may acquire the effects of vitamin D supplementation²⁰. However, administering vitamin D to participants who meet the same criteria can give zero results with regard to a decrease in BP because of the shorter time of administration (only 8 weeks with almost the same dose)²⁵. In addition, an updated meta-analysis's results were similar to our study in that subgroup analysis showed vitamin D supplementation may reduce SBP and DBP in patients with low vitamin D status and hypertension⁵. Searching articles until the end of March 2019, our study provides the most up-to-date meta-analysis and strongly supports that vitamin D supplementation significantly decreases BP in the elderly, specifically with elevated BP and deficiency in vitamin D.

In addition to hypertension patients, T2DM patients also exhibit a decrease in BP, although only SBP, after a high dose of vitamin D supplementation^{21,26}. Again, serum 25(OH)D levels also contributed to the effects of vitamin D supplementation on lowering BP. Pre diabetic patients reveal absolutely no effect of the same dose of vitamin D on BP because they are not vitamin D deficient²⁴. Most of the RCTs included in this study reveal an insignificant decrease in BP after given a dose supplementation of vitamin D. In the case of ISH, which is common among the elderly, vitamin D supplementation is less effective. The reason is probably because vitamin D cannot decrease blood vessel stiffness and is effective only during the early stages of the disease. Hypertension in the elderly does not increase renin levels²². Other studies have revealed no effect of vitamin D supplementation on lowering BP in postmenopausal women¹⁷, chronic peripheral arterial disease patients²⁰, and the elderly without certain medical conditions^{16,18,19}. The actual conditions suffered by the elderly due to multiple chronic diseases and therefore multiple drugs should be considered as an important aspect that may influence the effects of vitamin D on BP.

This study had a few limitations. First, although we conducted a systematic review of peer-reviewed research, we did not include agency reports, dissertations, and conference proceedings. Second, we included only English-language RCTs. Third, the RCTs were heterogeneous with respect to demographic characteristics of the participants, the duration, and treatment dose.

Conclusions

Vitamin D deficiency is prevalent among the elderly, and vitamin D supplementation significantly increases serum 25(OH)D levels. The use of vitamin D supplementation appears to be beneficial in lowering BP, specifically in the elderly with hypertension and vitamin D deficiency. We recommend vitamin D supplementation for elderly individuals with hypertension and serum 25(OH) D levels below the target

values. The actual conditions suffered by the elderly because of multiple chronic diseases and therefore multiple drugs should be considered as important factors that influence the effects of vitamin D on BP. The homogenous duration, dose intervention, and treatment regimen need to be investigated in future studies in order to determine the proper treatment for hypertension in the elderly.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Extended data

Open Science Framework: Extended data for “Effects of vitamin D supplementation on 25(OH)D levels and blood pressure in the elderly: a systematic review and meta-analysis.” <http://doi.org/10.17605/OSF.IO/EXF26>²⁸.

This project contains the following extended data:

- Spreadsheets in .sav format containing data for supplementation efficacy outcomes in 25(OH) levels, systolic blood pressure, and diastolic blood pressure.
- Supplementary figure in .doc format containing: Figure S1: results for quality assessment, Figure S2: forest plot of each subgroup analysis, Figure S3: Funnel plot and egger test results.

Reporting guidelines

Open Science Framework: Extended data for “Effects of vitamin D supplementation on 25(OH)D levels and blood pressure in the elderly: a systematic review and meta-analysis.” <http://doi.org/10.17605/OSF.IO/EXF26>²⁸.

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

References

- Robles N, Macias J: **Hypertension in the Elderly.** *Cardiovasc Hematol Agents Med Chem.* 2015; **12**(3): 136–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Handschin A, Henny-Fullin K, Buess D, *et al.*: [Hypertension in the elderly]. *Ther Umsch.* 2015; **72**(6): 397–403.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ke L, Mason RS, Kariuki M, *et al.*: **Vitamin D status and hypertension: A review.** *Integr Blood Press Control.* Dove Medical Press Ltd.; 2015; **8**: 13–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Pilz S, Tomaschitz A, Ritz E, *et al.*: **Vitamin D status and arterial hypertension: A systematic review.** *Nat Rev Cardiol.* 2009; **6**(10): 621–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
- He S, Hao X: **The effect of vitamin D3 on blood pressure in people with vitamin D deficiency: A system review and meta-analysis.** *Medicine (Baltimore).* 2019; **98**(19): e15284.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Qi D, Nie X, Cai J: **The effect of vitamin D supplementation on hypertension in non-CKD populations: A systemic review and meta-analysis.** *Int J Cardiol.* Elsevier Ireland Ltd; 2017; **227**: 177–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kunutsor SK, Apekey TA, Steur M: **Vitamin D and risk of future hypertension: Meta-analysis of 283,537 participants.** *Eur J Epidemiol.* 2013; **28**(3): 205–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Qi D, Nie X, Wu S, *et al.*: **Vitamin D and hypertension: Prospective study and meta-analysis.** Slominski AT, editor. *PLoS One.* 2017; **12**(3): e0174298.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kweder H, Eidi H: **Vitamin D deficiency in elderly: Risk factors and drugs impact on vitamin D status.** *Avicenna J Med.* 2018; **8**(4): 139–146.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ageing and health.**
[Reference Source](#)
- Moher D, Liberati A, Tetzlaff J, *et al.*: **Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.** *PLoS Med.* 2009; **6**(7): e1000097.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Higgins JPT, Altman DG, Gotzsche PC, *et al.*: **The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.** *BMJ.* 2011; **343**(7829): d5928.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Book Series C, Higgins JP, Green S: **Cochrane Handbook for Systematic Reviews of Interventions.** THE COCHRANE COLLABORATION @. 2008.
[Reference Source](#)
- Higgins JPT, Thompson SG: **Quantifying heterogeneity in a meta-analysis.** *Stat Med.* 2002; **21**(11): 1539–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Egger M, Smith GD, Schneider M, *et al.*: **Bias in Meta-Analysis Detected by a Simple, Graphical Test.** *BMJ.* 1997; **315**(7109): 629–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wood AD, Secombes KR, Thies F, *et al.*: **Vitamin D₃ supplementation has no effect on conventional cardiovascular risk factors: A parallel-group, double-blind, placebo-controlled RCT.** *J Clin Endocrinol Metab.* 2012; **97**(10): 3557–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gepner AD, Ramamurthy R, Krueger DC, *et al.*: **A prospective randomized controlled trial of the effects of Vitamin D supplementation on cardiovascular disease risk.** *PLoS One.* 2012; **7**(5): e36617.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sluyter JD, Camargo CA, Stewart AW, *et al.*: **Effect of monthly, high-dose, long-term vitamin D supplementation on central blood pressure parameters: A randomized controlled trial substudy.** *J Am Heart Assoc.* 2017; **6**(10): e006802.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Tomson J, Hin H, Emberson J, *et al.*: **Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1 Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D).** *J Am Heart Assoc.* 2017; **6**(10): e005707.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Larsen T, Mose FH, Bech JN, *et al.*: **Effect of cholecalciferol supplementation during winter months in patients with hypertension: A randomized, placebo-controlled trial.** *Am J Hypertens.* 2012; **25**(11): 1215–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Witham MD, Dove FJ, Dryburgh M, *et al.*: **The effect of different doses of vitamin D₃ on markers of vascular health in patients with type 2 diabetes: A randomised controlled trial.** *Diabetologia.* 2010; **53**(10): 2112–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Witham MD, Price RJG, Struthers AD, *et al.*: **Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the ViDiSH randomized controlled trial.** *JAMA Intern Med.* 2013; **173**(18): 1672–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chen WR, Liu ZY, Shi Y, *et al.*: **Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: A randomized placebo-controlled trial.** *Atherosclerosis.* 2014; **235**(1): 102–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sollid ST, Hutchinson MYS, Fuskevåg OM, *et al.*: **No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes.** *Diabetes Care.* 2014; **37**(8): 2123–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pilz S, Gaksch M, Kienreich K, *et al.*: **Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors: A Randomized Controlled Trial.** *Hypertension.* 2015; **65**(6): 1195–201.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sugden JA, Davies JI, Witham MD, *et al.*: **Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels.**

- Diabet Med.* 2008; **25**(3): 320–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Stricker H, Tosi Bianda F, Guidicelli-Nicolosi S, *et al.*: **Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in patients with peripheral arterial disease: A randomised controlled pilot study.** *Eur J Vasc Endovasc Surg.* 2012; **44**(3): 307–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Yogiswara N, Farapti F, Fadilla C: **Extended data for: "Effects of vitamin D supplementation on 25 (OH)D levels and blood pressure in the elderly: a systematic review and meta-analysis".** 2020.
<http://www.doi.org/10.17605/OSF.IO/NWUCA>
 29. Holick MF, Binkley NC, Bischoff-Ferrari HA, *et al.*: **Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline.** *J Clin Endocrinol Metab.* 2011; **96**(7): 1911–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Boucher BJ: **The problems of vitamin D insufficiency in older people.** *Aging Dis.* 2012; **3**(4): 313–29.
[PubMed Abstract](#) | [Free Full Text](#)
 31. Zittermann A: **Vitamin D and disease prevention with special reference to cardiovascular disease.** *Prog Biophys Mol Biol.* Elsevier Ltd; 2006; **92**(1): 39–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Vera V, Setiati S, Roosheroe AG: **Determinan Diagnostik Klinis Defisiensi Vitamin D pada Wanita Berusia Lebih dari 50 Tahun.** *J Penyakit Dalam Indones.* 2015; **2**(1): 38.
[Publisher Full Text](#)
 33. Russell RM: **Factors in aging that effect the bioavailability of nutrients.** *J Nutr.* 2001; **131**(4 Suppl): 1359S–61S.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Gallagher JC: **Vitamin D and Aging.** *Endocrinol Metab Clin North Am.* 2013; **42**(2): 319–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Golzarand M, Shab-Bidar S, Koochakpoor G, *et al.*: **Effect of vitamin D3 supplementation on blood pressure in adults: An updated meta-analysis.** *Nutr Metab Cardiovasc Dis.* 2016; **26**(8): 663–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Witham MD, Nadir MA, Struthers AD: **Effect of vitamin D on blood pressure: A systematic review and meta-analysis.** *J Hypertens.* 2009; **27**(10): 1948–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Vaidya A, Williams JS: **The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes.** *Metabolism.* 2012; **61**(4): 450–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 18 August 2020

<https://doi.org/10.5256/f1000research.27711.r69387>

© 2020 Boucher B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Barbara J. Boucher

The Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

This review and meta-analysis of previous studies on the effects of vitamin D supplementation on vitamin D status and on blood pressure in the elderly is a topic of importance for population health since hypertension and vitamin D deficiency are both so common in elderly people globally, including isolated systolic hypertension. This manuscript has already been assessed by earlier peer review as being appropriate in design and analytical methodology. The present comments, therefore, are mainly directed at presentation, readability and the additional information requested by the previous reviewers. It is unfortunate that only 8 of the many RCTs considered for this study were suitable for meta-analysis. The use of Individual Participant Data, if obtainable, could be more revealing on the question of whether supplementation is more effective for reducing BP in older people in deficiency than in repletion, as suspected in other health problems and as the present data suggests. This would be a valuable follow-on study if it were to be possible.

General comments:

1. The English language usage is often awkward, which distracts from the readability of the text. Simple editing by a native English language speaker with a scientific/medical background would greatly improve the readability of the text throughout.
2. Vitamin D was not measured in any studies analysed, but 25-hydroxyvitamin D [25OHD], and this term should be used throughout. Lab data reports 'concentrations' not 'levels' and this term should be used while 'levels' is good for cut-offs and definitions.

Specific comments:

- Table 2, the heading 'vitamin D' would be clearer saying 'baseline vitamin D status'.
- Page 10, column 1, line 2, do you mean decreases by 75% or decreases by 25% - please clarify; line 3, ..have..; 2nd column, line 6, do you mean '...reduce renal activation, [though

not that in other target tissues], but such problems were amongst the exclusion criteria'?

- Page 10, 2nd column, para 2, the last sentence reads as if this is the 1st study to assess the effects of supplementation on serum 25OHD values but this cannot be true either for this submission or for the 'newer' meta-analysis mentioned in the previous sentence that needs a reference. These comments should be corrected - maybe you mean '...in elderly people for both vitamin D status and effects on blood pressure'?
- Page 11, 1st column, line 15, 'adjunctive' might be a better word than 'supportive'; Para 2, line 4, '...have confirmed the association' might be better than proven & '...however associations are not proof of causality'; column 2, 1st para, lines 6/7 are obscure, this section reads as if deficiency lowers blood pressure, which is not what is meant - maybe say, re. ref 24, '...because they were not vitamin D deficient'. Re ref 22 comment, it would be better to say that circulating renin concentrations are not raised in the elderly and not the other way around as renin raises the BP and is suppressed by vitamin D, [if you are sure that this is a general finding]. Para 3, do you mean that supplemental doses were heterogeneous or that treatments for hypertension were heterogeneous, or, as I suspect, that both of these were heterogeneous? Please clarify.
- Page 12, para 1, is unclear, if you mean that studies homogeneous for duration, etc, need to be carried out, please rephrase for clarity, perhaps concluding, '...so as to identify optimal treatment regimes for hypertension in the elderly that may need to include correction of vitamin D deficiency'?

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: diabetes, metabolism, vitamin d and betel quid chewing.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 04 Sep 2020

Niwanda Yogiswara, Universitas Airlangga, Surabaya, Indonesia

We appreciate Professor Barbara Joan Boucher for her time, constructive comments, and

for recommending approval of our paper.

The major recommendations for improvement are two:

First, "The English language usage is often awkward, which distracts from the readability of the text. Simple editing by a native English language speaker with a scientific/medical background would greatly improve the readability of the text throughout." We have tried to revise some sentence misconstruction and also improve the English language. Every specific comment and suggestion indicated by the Reviewer has been precisely considered, and we hope satisfactorily addressed.

Second, the Reviewer points out that the paper should use the term 'concentrations' not 'levels'. This is an important suggestion since lab data reports 'concentrations' not 'levels', we have replaced the term 'levels' with 'concentrations', except for cut-off and definitions.

Again, we thank Prof. Boucher for giving her valuable insight with very detailed comments, which we feel have significantly improved paper readability.

Competing Interests: No competing interests were disclosed.

Reviewer Report 05 August 2020

<https://doi.org/10.5256/f1000research.27711.r68253>

© 2020 Silva A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alexandre S. Silva

Postgraduate Program in Nutrition Sciences-Postgraduate Program in Physical Education, Federal University of Paraíba, João Pessoa, Brazil

It is a review with a well-structured meta-analysis, following Cochrane principles. Compared to other previous meta-analyses, the present review differs in that it performed the analysis in the elderly population. Although it has been noticed that this manuscript has already been revised, I still see some small issues that can be improved, especially to ensure the replicability of the methodology. This and other questions are presented below.

Introduction:

- Second paragraph: I suggest the authors to present the biological rationale of hypovitaminosis D with arterial hypertension (before presenting the results of some meta-analyses).

Methods:

- The authors presented the PubMed search strategy only. I suggest presenting the other

strategies, so that the methodology is replicable.

- One of the exclusion criteria was: "assessment of the full text of the study not possible". This actually happened? I suggest that the authors identify these studies and present the difficulties to access this study (s). Important for the replication of the methodology.

Discussion:

- I missed the clinical implications of this study. Do data provide evidence for the use of vitamin D for hypertensive elderly people? Although significant, does the observed reduction in blood pressure really have clinical relevance compared to other interventions?

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Partly

Are sufficient details of the methods and analysis provided to allow replication by others?

Partly

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Nutrition, exercise and Hypertension; Nutrition, exercise and weight loss; Fresh food as ergogenic aid for athletes; nut

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 04 Sep 2020

Farapti Farapti, Universitas Airlangga, Surabaya, Indonesia

We thank the editors for facilitating the peer-review process and we appreciate Professor Silva's positive opening remarks and his expert review and suggestions for improving the paper. We have uploaded a revised copy of the manuscript.

The specific recommendations for improvement are four:

First, the Reviewer suggested that the paper should "present the biological rationale of hypovitaminosis D with arterial hypertension before presenting the results of some meta-analyzes". In the revised paper, we have now added the sentence to present the biological rationale of hypovitaminosis D with arterial hypertension in the introduction paragraph two.

Second, the Reviewer suggested that the paper should present the strategy used in other databases. In our revision, we have added the information regarding other strategies used in Cochrane Library and Clinicaltrial.gov so that the methodology is replicable.

Third, "One of the exclusion criteria was: "assessment of the full text of the study not possible". This actually happened? I suggest that the authors identify these studies and present the difficulties to access this study (s). Important for the replication of the methodology". We are sorry that we used a phrase that leads to sentence misconstruction. The sentence "assessment of the full text of the study not possible" should be written by "no full text available."

Fourth, "I missed the clinical implications of this study. Do data provide evidence for the use of vitamin D for hypertensive elderly people? Although significant, does the observed reduction in blood pressure really have clinical relevance compared to other interventions?"

This is an important question and we have addressed it directly in the revision. In the revised paper, we now incorporate the study's clinical implication and cite the relevant papers regarding clinical relevance compared to other intervention in the discussion section. We thank Prof. Silva for calling our attention to these ideas.

Finally, we thank Professor Silva for raising these points which we feel have improved the paper considerably.
Farapti, et al.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research